Abbott EVP Lisa Earnhardt granted stock options

Earnhardt Lisa D reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Earnhardt Lisa D reported acquisition or exercise transactions in this Form 4 filing.

Abbott Laboratories executive Lisa D. Earnhardt, EVP and Group President, reported equity awards on February 24, 2026. She was granted stock options covering 111,533 options and a performance-based restricted stock award of 27,056 common shares under the Abbott Laboratories 2017 Incentive Stock Program.

The restricted stock award has a three-year term, with no more than one-third vesting in any year and vesting tied to Abbott reaching a minimum return-on-equity target. The award allows shares to be withheld for taxes. The stock option becomes exercisable in increments of 37,177 and 37,178 shares on February 24, 2027, February 24, 2028, and February 24, 2029.

Insider Trade Summary

Grant/Award: 138,589 shares

Grant/Award 2 txns

Insider Earnhardt Lisa D

Role EVP AND GROUP PRESIDENT

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	111,533	$0.00	$0.00
Grant/Award	Common shares without par value	27,056	$0.00	$0.00

Holdings After Transaction: Option (right to buy) — 111,533 contracts (Direct); Common shares without par value — 98,984 shares (Direct)

Footnotes (2)

1. F1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
2. F2. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 37,177 on February 24, 2027, 37,178 on February 24, 2028, and 37,178 on February 24, 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lisa D. Earnhardt receive in this Abbott (ABT) Form 4 filing?

Lisa D. Earnhardt reported receiving two equity awards from Abbott Laboratories: stock options covering 111,533 shares and a performance-based restricted stock award of 27,056 common shares, all granted under the Abbott Laboratories 2017 Incentive Stock Program on February 24, 2026.

What are the terms of Lisa Earnhardt7s performance-based restricted stock award at Abbott (ABT)?

The performance-based restricted stock award covers 27,056 Abbott common shares and has a three-year term. No more than one-third of the award can vest in any one year, and vesting requires Abbott to reach a minimum return-on-equity target, with shares eligible to be withheld for taxes.

When do Lisa Earnhardt7s Abbott stock options from this grant become exercisable?

The employee stock option for 111,533 Abbott shares becomes exercisable in three annual increments. It vests for 37,177 options on February 24, 2027, 37,178 options on February 24, 2028, and 37,178 options on February 24, 2029, according to the grant terms disclosed.

How many Abbott common shares does Lisa Earnhardt hold directly after these Form 4 transactions?

After the reported grant of 27,056 performance-based restricted shares, Lisa D. Earnhardt directly holds a total of 98,984 Abbott common shares. This figure reflects her direct common share ownership immediately following the February 24, 2026 equity award transaction.

Are the transactions in this Abbott (ABT) Form 4 open-market buys or equity grants?

The transactions reported are equity grants, not open-market purchases. Lisa D. Earnhardt acquired stock options and performance-based restricted stock as awards under the Abbott Laboratories 2017 Incentive Stock Program, categorized as grant, award, or other acquisition transactions.

What vesting conditions apply to Lisa Earnhardt7s performance-based Abbott shares?

The 27,056-share performance-based award vests over three years, with no more than one-third vesting in any single year. Actual vesting depends on Abbott achieving at least a minimum return-on-equity target, and the award includes the right to have shares withheld to cover taxes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 06:11 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Earnhardt Lisa D

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP AND GROUP PRESIDENT

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	02/24/2026		A		27,056(1)	A	$0	98,984	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)(2)	$114.6	02/24/2026		A		111,533		02/24/2027	02/23/2036	Common Shares	111,533	$0	111,533	D

Explanation of Responses:

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

2. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 37,177 on February 24, 2027, 37,178 on February 24, 2028, and 37,178 on February 24, 2029.

	/s/ Lisa D. Earnhardt, by Jessica H. Paik, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.